Vikram Purohit
Stock Analyst at Morgan Stanley
(1.81)
# 3,309
Out of 5,147 analysts
163
Total ratings
32.31%
Success rate
-7.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Overweight | $11 → $18 | $6.90 | +160.87% | 3 | Feb 18, 2026 | |
| INCY Incyte | Maintains: Equal-Weight | $92 → $94 | $101.27 | -7.18% | 26 | Jan 6, 2026 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $26.35 | +29.03% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $69.53 | +13.62% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $2.74 | +114.96% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $3.67 | +36.24% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $233.50 | +7.07% | 19 | May 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $163.89 | +15.93% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $5.68 | +58.45% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $29.44 | +5.30% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $121.28 | -86.81% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $26.97 | -62.92% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $13.97 | -57.05% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $9.04 | +364.60% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $91.35 | -55.12% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $8.90 | +349.44% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.24 | +480.36% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $12.06 | +215.09% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $7.08 | +182.49% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $18.25 | -45.21% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.06 | +1,975.47% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $20.99 | -4.72% | 2 | Aug 5, 2020 |
COMPASS Pathways
Feb 18, 2026
Maintains: Overweight
Price Target: $11 → $18
Current: $6.90
Upside: +160.87%
Incyte
Jan 6, 2026
Maintains: Equal-Weight
Price Target: $92 → $94
Current: $101.27
Upside: -7.18%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $26.35
Upside: +29.03%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $69.53
Upside: +13.62%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $2.74
Upside: +114.96%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $3.67
Upside: +36.24%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $233.50
Upside: +7.07%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $163.89
Upside: +15.93%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $5.68
Upside: +58.45%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $29.44
Upside: +5.30%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $121.28
Upside: -86.81%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $26.97
Upside: -62.92%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $13.97
Upside: -57.05%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $9.04
Upside: +364.60%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $91.35
Upside: -55.12%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $8.90
Upside: +349.44%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.24
Upside: +480.36%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $12.06
Upside: +215.09%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $7.08
Upside: +182.49%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $18.25
Upside: -45.21%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.06
Upside: +1,975.47%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $20.99
Upside: -4.72%